Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Ding, Miao ^a   Cao, Xin ^a   Xu, Hai neng ^a   Fan, Jun kai ^c   Huang, Hong ling ^a   Yang, Dong qin ^a   Li, Yu hua ^d   Wang, Jian ^d   Li, Runsheng ^d   Liu, Xin Yuan ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AD.DD3.D55 PTEN; ADENOVIRUS VECTOR; E1A PROTEIN; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; PTEN PROTEIN, HUMAN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DD3 GENE; E1A GENE; ENZYME INACTIVATION; GENE; GENE EXPRESSION; GENE INSERTION; GENETIC TRANSCRIPTION; GROWTH RATE; HUMAN; HUMAN CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PTEN GENE; WOODCHUCK; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; METHODOLOGY; NUDE MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

MARMOTA MONAX;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 84859621569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035153     Document Type: Article

References (55)

1. Denmeade SR, Isaacs JT, (2004) Development of prostate cancer treatment: the good news. Prostate 58: 211-224.
2. Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, et al. (2007) Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res 67: 5434-5442.
3. Huggins C, Hodges CV, (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: 9-12.
4. Wolfert MA, Schacht EH, Toncheva V, Ulbrich K, Nazarova O, et al. (1996) Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers. Hum Gene Ther 7: 2123-2133.
5. Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, et al. (1999) Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther 6: 1438-1447.
6. Berkner KL, (1988) Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6: 616-629.
7. Berkner KL, (1992) Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 158: 39-66.
8. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
9. Kirn D, (2001) Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 1: 525-538.
10. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, et al. (2003) An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13: 481-489.
11. Zhang Q, Nie M, Sham J, Su C, Xue H, et al. (2004) Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 64: 5390-5397.
12. Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, et al. (2009) Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene Ther 20: 818-830.
13. Schmidt C, (2011) Amgen spikes interest in live virus vaccines for hard-to-treat cancers. Nat Biotechnol 29: 295-296.
14. Evans J, (2011) Recent deal highlights hopes for cancer-killing viruses. Nat Med 17: 268-269.
15. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, et al. (2002) DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698.
16. Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ, (2000) Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 275: 37496-37503.
17. Fan JK, Wei N, Ding M, Gu JF, Liu XR, et al. (2009) Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. Int J Cancer.
18. Klein R, Ruttkowski B, Knapp E, Salmons B, Gunzburg WH, et al. (2006) WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene 372: 153-161.
19. Mastroyiannopoulos NP, Feldman ML, Uney JB, Mahadevan MS, Phylactou LA, (2005) Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3′ untranslated region transcripts. EMBO Rep 6: 458-463.
20. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, et al. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551-2556.
21. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, et al. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296.
22. Pellinen R, Hakkarainen T, Wahlfors T, Tulimaki K, Ketola A, et al. (2004) Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy. Int J Oncol 25: 1753-1762.
23. Gropp M, Itsykson P, Singer O, Ben-Hur T, Reinhartz E, et al. (2003) Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther 7: 281-287.
24. Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ, (1999) Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 10: 2295-2305.
25. Gonzalez-Murillo A, Lozano ML, Alvarez L, Jacome A, Almarza E, et al. (2009) Development of lentiviral vectors with optimized transcriptional activity for the gene therapy of patients with Fanconi anemia. Hum Gene Ther 21: 623-630.
26. Cheng WS, Dzojic H, Nilsson B, Totterman TH, Essand M, (2006) An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther 13: 13-20.
27. Muthana M, Giannoudis A, Scott SD, Fang HY, Coffelt SB, et al. (2011) Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res 71: 1805-1815.
28. Li X, Zhang YP, Kim HS, Bae KH, Stantz KM, et al. (2005) Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res 65: 1941-1951.
29. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, et al. (2001) Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 8: 628-635.
30. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, et al. (2000) a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
31. Kim J, Coetzee GA, (2004) Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 93: 233-241.
32. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, et al. (1998) The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58: 5667-5672.
33. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, et al. (1998) Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8: 1195-1198.
34. Klarlund JK, Guilherme A, Holik JJ, Virbasius JV, Chawla A, et al. (1997) Signaling by phosphoinositide-3,4,5-trisphosphate through proteins containing pleckstrin and Sec7 homology domains. Science 275: 1927-1930.
35. Li E, Stupack D, Bokoch GM, Nemerow GR, (1998) Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol 72: 8806-8812.
36. Li E, Stupack D, Klemke R, Cheresh DA, Nemerow GR, (1998) Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-OH kinase. J Virol 72: 2055-2061.
37. O'Shea CC, Choi S, McCormick F, Stokoe D, (2005) Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 4: 883-888.
38. Teng DH, Hu R, Lin H, Davis T, Iliev D, et al. (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221-5225.
39. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98: 11563-11568.
40. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221.
41. Zhou YA, Zhang T, Zhao JB, Wang XP, Jiang T, et al. (2010) The adenovirus-mediated transfer of PTEN inhibits the growth of esophageal cancer cells in vitro and in vivo. Biosci Biotechnol Biochem 74: 736-740.
42. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, et al. (1998) Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 58: 2331-2334.
43. Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, et al. (1999) Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 59: 6063-6067.
44. Sakurada A, Hamada H, Fukushige S, Yokoyama T, Yoshinaga K, et al. (1999) Adenovirus-mediated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int J Oncol 15: 1069-1074.
45. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, et al. (2000) MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19: 5406-5412.
46. Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, et al. (2003) Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther 10: 1961-1969.
47. Hang Y, Zheng YC, Cao Y, Li QS, Sui YJ, (2005) Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol 11: 2224-2229.
48. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, et al. (2002) Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8: 1904-1914.
49. Qiu Z, Cui FL, Xu CL, Gu ZQ, Sun YH, (2007) [Suppression of invasion and angiogenesis in human prostate cancer PC-3 cells by adenovirus-mediated co-transfer of PTEN and P27]. Zhonghua Nan Ke Xue 13: 201-205.
50. Tanaka M, Rosser CJ, Grossman HB, (2005) PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Detect Prev 29: 170-174.
51. Qiu Z, Sun YH, Xu CL, Wang YT, Gu ZQ, et al. (2004) [PTEN and p27Kip1 have a cooperative role on inhibition proliferation, modulation of cell cycle and inducing apoptosis in prostate cancer PC-3 cell]. Zhonghua Wai Ke Za Zhi 42: 600-603.
52. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, et al. (2004) Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 11: 273-279.
53. Skjoth IH, Issinger OG, (2006) Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 28: 217-229.
54. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, et al. (2000) Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 6: 220-233.
55. Zhao L, Gu J, Dong A, Zhang Y, Zhong L, et al. (2005) Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16: 845-858.